VIRO ViroGates A/S
ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic TurbiLatex, a CE-IVD approved particle-enhanced turbidimetric immunoassay for quantitative measurement of suPAR in human plasma; suPARnostic AUTO Flex ELISA kit, a fully quantitative immunoassay designed for accurate and reliable measurement of soluble urokinase plasminogen activator receptor in human plasma; and suPARnostic Quick Triage, a test for rapid, quantitative measurement of suPAR levels. ViroGates A/S was founded in 2000 and is headquartered in Birkerød, Denmark.…
Industry Peers
Medical DevicesKey Statistics
About ViroGates (CPH: VIRO)
›
ViroGates (CPH: VIRO) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 7 employees.
The shares were at 7.100 DKK on 19 November 2026, down 44.3% over 52 weeks. Its 52-week range is 6.050 DKK to 17.40 DKK: the price is 59.2% below the high and 17.4% above the low.
Its market capitalisation is 65.90M DKK.
ViroGates reports return on equity of -53.6%, an operating margin of -104.7% and revenue down 33.6% year over year.
It holds more cash than debt, a net cash position of 11.25M DKK. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.